Terms governing antibody design and antibody engineering services from Abtique
This summary is for convenience only and is not legally binding. The full Terms control. Periods and amounts below are the defaults; your Order may state different ones.
Computationally designed amino-acid sequences, delivered digitally, in Rounds. An Initial Round is the first set. A Follow-on Round redesigns using the Experimental Results you send back. You can buy Rounds together, which reserves our capacity for the later Rounds and prices them lower than buying them separately.
After your Order is accepted, we send you a Design Plan before we generate anything. Nothing starts until you approve it by email. When you send back Experimental Results, we issue a new Design Plan for the next Round and the cycle repeats.
You have a set period, 12 months unless your Order says otherwise, to use everything in your Order. It starts when you approve the first Design Plan. If we are waiting on your Experimental Results, we hold the next Round, and that time still counts. Time lost to our own delay does not. After the period ends, an unused Round expires.
Once you have paid the fees for a Round, the Sequences delivered in that Round are yours. We keep our technology, models and methods.
Each Sequence we deliver is exclusive to you, at no extra charge, for a Free Exclusivity Period stated in your Order (12 months from delivery unless your Order says otherwise). During that period we withhold it from everyone else. We will write to you at least 60 days before that period ends. You then have until 30 days after the period ends to decide, Sequence by Sequence, whether to subscribe to keep exclusivity, for the monthly fee stated in your Order. While you subscribe, we keep withholding that exact Sequence. If you do not subscribe, our promise to withhold that Sequence ends and we are free to provide it to others, though we are not obliged to. You still own your copy. You can also make exclusivity permanent with a one-time Buyout, priced as a multiple of the monthly fee in effect when you buy. A Buyout is cheapest before the first monthly fee is due.
Your data stays yours. We use it only to design your Sequences and to improve models used solely for your programs. We do not use it to train, fine-tune or improve any model used for any other client, and we do not share it. Unless you opt out, we may mention the target class of your work in anonymized promotional material that does not identify you or your Sequences.
Everything we deliver is computational, not experimentally validated. There is no (1) wet-lab work, (2) materials, (3) manufacturing, (4) Feasibility Assessment (that is a separate purchase under separate terms), or (5) freedom-to-operate or patentability advice.
Sequences are provided AS IS. Each party’s total liability is capped at what you paid for the Rounds in the corresponding Order, with the usual exceptions for misuse, indemnities, intentional breach and willful misconduct. If we breach a Sequence's exclusivity, you can get an injunction and a refund of the subscription and Buyout fees you paid for that Sequence. You can terminate if we materially breach and do not cure it within 30 days. Disputes go to JAMS arbitration seated in New York, held by videoconference by default.
1.1 These Abtique Terms of Service (the "Terms") govern antibody design and antibody engineering services that EVQLV, Inc., a Delaware corporation operating under the Abtique brand ("EVQLV"), performs for a customer ("Client") under an EVQLV order form or quote that references them (an "Order").
1.2 Client accepts an Order and these Terms by signing the Order, issuing a purchase order referencing it, accepting online or by clickthrough, or paying EVQLV's invoice for it. The date of the first of these is the "Effective Date." The Order, these Terms, and each Design Plan that receives Design Approval under them are together the "Agreement," and EVQLV and Client are each a "Party."
1.3 The version of these Terms stated in an Order governs that Order. Later versions do not apply to it. EVQLV may retain electronic records of acceptance and Order details, and such records are admissible to prove formation and terms.
1.4 Precedence. As to the subject matter of an Order: the Order controls over these Terms only as to the items the Order exists to state (Client details, fees, the Rounds purchased, the variable values listed in Section 2.4, and any Special Terms); these Terms control over the Order in all other respects; the Design Plan controls scope as described in Section 3; and these Terms control over any confidentiality agreement between the Parties as to services performed under an Order, notwithstanding any term of that agreement requiring a later agreement to refer to it expressly. Any deviation from these Terms that EVQLV agrees to is stated in a section of the Order titled "Special Terms" and controls over these Terms to the extent stated there. Any confidentiality agreement between the Parties continues to govern information disclosed outside an Order.
1.5 Posted pricing is conditioned on acceptance of these Terms. A counterparty that requires its own services agreement, or that materially amends these Terms, does not qualify for posted pricing and is separately quoted. This condition applies to these Terms only; a Client using its own confidentiality agreement remains eligible for posted pricing, and Special Terms that EVQLV states in an Order do not affect eligibility for posted pricing.
1.6 Each person accepting an Order for a Party represents that they are authorized to bind that Party. Client represents that it is an entity acquiring the services in the course of its business and that it is purchasing for research use only, as described in Section 11.1.
2.1 "Sequence" means an amino-acid sequence generated by EVQLV and delivered to Client under an Order, whether designed de novo or engineered from sequences Client supplies. EVQLV delivers variable domain sequences only. Unless the Order states otherwise, one Sequence is one single-domain (VHH) antibody sequence or one paired heavy-chain and light-chain (VH/VL) variable domain sequence. "Same Sequence" means a sequence identical over the full length of a delivered Sequence, including both chains of a paired Sequence.
2.2 "EVQLV Technology" has the meaning in Section 6.2. "Client Data" has the meaning in Section 9.1. "Design Approval" and "Approval Date" have the meanings in Section 3.3. "Exclusivity Covenant" has the meaning in Section 7.1.
2.3 “Experimental Results” means Client Data consisting of the results of Client’s testing of the Sequences delivered in a Round, which Client provides to EVQLV for the purpose of EVQLV designing a Follow-on Round (as defined in Section 4.1).
2.4 Variable Terms. Some commercial terms vary from Order to Order, such as fees, time periods and the number of Sequences. Each of these "Variable Terms" is stated in the Order. If the Order does not state a value, the default in the table below applies.
| Variable Term | Default if the Order is silent |
|---|---|
| Fee for each Round | No default; must be stated separately for each Round |
| Number of Sequences in a Round | As stated in the Order; a Design Plan may increase but not reduce it |
| Program Term | Twelve (12) months, running as stated in Section 5.1 |
| Design Plan Response Period | Thirty (30) days from issuance |
| Design Plan Charge | The published price for an Abtique Feasibility Assessment on the date the Order is issued or, if none is then published, the last published price |
| Free Exclusivity Period | Twelve (12) months from Delivery of the Sequence |
| Subscription Notice Period | Sixty (60) days before the end of the Free Exclusivity Period |
| Subscription Grace Period | Thirty (30) days after the end of the Free Exclusivity Period |
| Subscription Fee | No default; must be stated for the subscription to operate |
| Escalation Interval | No default; absent a stated interval the Subscription Fee does not escalate |
| Escalation Amount | No default; absent a stated amount the Subscription Fee does not escalate |
| Buyout Multiple | No default; must be stated for a Buyout to be available |
| Prepayment term and any associated discount | None |
| Round Buyout Price | None; if stated, Client may buy out all Sequences delivered in a Round at that price |
| Patent assistance rates | USD $1,000 per hour for EVQLV partners and executives; USD $750 per hour for other staff |
| Special Terms | None |
EVQLV may change any of these values for future Orders without amending these Terms. No change affects an Order that has already been accepted unless both Parties agree to it in advance in a writing signed by both.
3.1 Overview. Each engagement proceeds as follows: (a) Client accepts an Order; (b) EVQLV issues a Design Plan for the Initial Round; (c) Client gives Design Approval, and EVQLV generates and delivers the Sequences for that Round; (d) Client tests the Sequences and may submit Experimental Results; and (e) for each Follow-on Round purchased, EVQLV analyzes the Experimental Results and issues a new Design Plan, and steps (c) through (e) repeat. All Rounds must be completed within the Program Term under Section 5.
3.2 Issuance of a Client Design Plan. Before generating Sequences for a Round, EVQLV will issue Client a Design Plan stating the target or targets, the number of Sequences to be generated, which may not be fewer than the number stated in the Order, the scope of the work for that Round, and any performance commitment EVQLV offers for the Round, together with Client's sole remedy if that commitment is not met.
3.3 Design Approval. Client approves a Design Plan by email to EVQLV ("Design Approval"). EVQLV will not begin work on a Design Plan until it receives Design Approval, and the date of Design Approval is the "Approval Date." EVQLV will issue each Design Plan to the Client notice contact stated in the Order, and each Design Plan states the Design Plan Response Period on its face. If Client neither gives Design Approval nor objects within the Design Plan Response Period, EVQLV will not begin work, and Section 5.4 applies.
3.4 Objection. If Client objects to a Design Plan within the Design Plan Response Period, EVQLV will revise and reissue it at least once, and a new Design Plan Response Period runs from reissuance. If Client does not give Design Approval to the reissued Design Plan, EVQLV may terminate the Order as to the undelivered Rounds on written notice. On that termination, (a) if no Round has been delivered under the Order, EVQLV will refund the fees paid for the undelivered Rounds, less the Design Plan Charge, which compensates EVQLV for preparing the Design Plans and will not exceed those fees; and (b) if a Round has been delivered under the Order, Section 10.3 applies and the fees for the undelivered Rounds are not refunded.
3.5 Scope. The Design Plan that receives Design Approval controls the scope of the Round it covers, and these Terms control the terms on which it is performed. Where a Design Plan and these Terms conflict as to anything other than scope or a performance commitment under Section 3.7, these Terms control. Ownership of each Design Plan, and Client’s permitted use of it, are governed by Section 6.5.
3.6 Subsequent Design Plans. After Client submits Experimental Results under Section 4.3 and EVQLV completes its analysis of them, EVQLV will issue a Design Plan for the next Round. Sections 3.2 to 3.5 apply to each Design Plan.
3.7 Performance commitments. No Round carries any guarantee, commitment, or representation as to outcome except as expressly stated in the Design Plan for that Round and subject to the conditions stated there. Any such commitment, and Client's sole remedy if it is not met, are stated in that Design Plan, apply notwithstanding Section 12.1, and are subject to Section 13. Marketing and promotional material of any kind is not part of the Agreement.
4.1 "Round" means one cycle of Sequence generation under a Design Plan that has received Design Approval. An "Initial Round" is a Round designed without Experimental Results from an earlier Round. A "Follow-on Round" is a Round designed using Experimental Results from a preceding Round that Client submits under Section 4.3. An Order may include one or more Follow-on Rounds.
4.2 Combined Purchase. Where an Order includes both an Initial Round and one or more Follow-on Rounds, EVQLV reserves capacity for the Follow-on Rounds for the Program Term. That reservation is part of the consideration for the combined price. A Follow-on Round may also be purchased separately at the price then posted or quoted.
4.3 Experimental Results for a Follow-on Round. A Follow-on Round is designed using Experimental Results that Client generates and submits to EVQLV. Client determines what to test and what to submit.
4.4 No minimum data standard. EVQLV applies no minimum usability standard to Experimental Results. The quality of a Follow-on Round depends on the completeness and quality of the Experimental Results supplied. No performance commitment in a Design Plan applies to a Round designed without Experimental Results, or from incomplete or poor-quality Experimental Results, unless that Design Plan says otherwise.
4.5 Obligation to deliver on submission. Where Client submits Experimental Results from the preceding Round, EVQLV will issue a Design Plan for the Follow-on Round and, on Design Approval, generate and deliver it. EVQLV's obligation to deliver does not depend on the completeness or quality of the Experimental Results submitted.
4.6 If Experimental Results are not submitted. EVQLV may delay commencement of a Follow-on Round only where Client has not submitted Experimental Results from the preceding Round. At Client’s written request, EVQLV will proceed with a Follow-on Round without Experimental Results, in which case Section 4.4 applies. EVQLV will not otherwise generate or deliver a Follow-on Round before Client has submitted Experimental Results from the preceding Round. A delay under this Section 4.6 does not extend the Program Term.
4.7 Delivery. "Delivery" is complete when EVQLV electronically transmits the Sequences for a Round to the account or email address identified in the Order.
5.1 All Rounds under an Order, and any performance commitment stated in a Design Plan, must be completed within the Program Term, which runs from the Approval Date of the first Design Plan issued under the Order. The Program Term is extended by one day for each day after the tenth (10th) business day following Client's submission of Experimental Results until EVQLV issues the Design Plan for the next Round.
5.2 At the end of the Program Term, any Round purchased but not delivered expires and the fee for it is forfeited, except that a Round that received Design Approval before the end of the Program Term does not expire, and EVQLV will deliver it. EVQLV will give Client written notice before expiration. That notice is a courtesy and not a condition of expiration.
5.3 EVQLV may, in its sole discretion, extend the Program Term for an Order. Any extension must be in writing.
5.4 Outside date. If Client has not given Design Approval to the first Design Plan issued under an Order within ninety (90) days after it is first issued, EVQLV may terminate the Order on written notice, and Section 3.4 applies to that termination.
6.1 Client's Sequences. On EVQLV's receipt of cleared payment of the fees for the Round in which they are delivered, EVQLV hereby assigns to Client all of its right, title and interest in the Sequences delivered in that Round, and those Sequences are, as between the Parties, Client's sole and exclusive property, subject to Section 7 and to EVQLV's retained rights in Section 6.2. That title is sufficient for Client to file patent applications on the Sequences. Client may use, modify, test, develop, publish, patent, sublicense, and commercialize them at its own risk. Client's ownership does not restrict EVQLV from generating, using or providing the Same Sequence or any other sequence for itself or any third party, except while an Exclusivity Covenant applies to that Sequence, provided EVQLV does not use Client Data or Client's Confidential Information in doing so.
6.2 EVQLV Technology. EVQLV retains all right, title and interest in all technology, methods, models, software, pipelines, templates, scoring functions, structural modeling and know-how used to generate, evaluate, select or deliver Sequences, together with all intermediate artifacts and outputs not expressly delivered as a Sequence, all data assets and associated database rights, and all modifications, enhancements, improvements and derivative works of the foregoing made by or for EVQLV (together, "EVQLV Technology"). Client hereby irrevocably assigns to EVQLV any rights it has in feedback and suggestions it gives EVQLV about EVQLV Technology. Neither EVQLV Technology nor that assignment extends to the Sequences, to Client Data, or to anything derived from Client Data, which is governed by Section 9.
6.3 Limited license to embedded technology. EVQLV grants Client a non-exclusive, worldwide, perpetual, royalty-free license to use any EVQLV technology or metadata embedded in a delivered Sequence, solely as incorporated in that Sequence, and not on a stand-alone basis or to develop, train, test, benchmark or improve any model, tool or workflow. Client will not reverse engineer, extract or reuse EVQLV Technology apart from the delivered Sequence.
6.4 Unaided memory. EVQLV personnel may use information retained in their unaided memories through ordinary-course interactions with Client to develop, enhance and provide products and services, provided EVQLV does not intentionally memorize, disclose or misuse Client's Confidential Information.
6.5 The Design Plan. Each Design Plan is EVQLV’s work product and the Confidential Information of EVQLV, and EVQLV owns it, except to the extent it contains Client’s Confidential Information, which remains Client’s. EVQLV grants Client a non-exclusive, non-transferable, royalty-free license to use each Design Plan internally, solely to evaluate it, give or withhold Design Approval, and receive and use the Sequences delivered under it. Client may disclose a Design Plan only to its employees, contractors, advisors, actual or prospective investors, acquirers, licensees and collaborators, patent offices and regulators, in each case only as needed for those purposes and, except for patent offices and regulators, only to persons bound by obligations no less protective than Section 14. Client may not disclose a Design Plan to any person that provides computational antibody design or engineering services. Client may not use a Design Plan, or any description in it of EVQLV’s methods, approach, selection criteria or workflow, to (a) develop, train, benchmark or evaluate any computational model, tool or workflow; (b) perform, or procure from any third party, the same or similar design or engineering work; or (c) develop or operate a service competing with EVQLV’s computational design business. Nothing in this Section 6.5 restricts Client’s own research, development or commercial activities, or its freedom to work with any third party, provided Client does not use the Design Plan, EVQLV's Confidential Information or EVQLV Technology in doing so.
6.6 Exclusions. Nothing in the Agreement grants either Party any right in a target, epitope, field-of-use, indication, modality, or any similarity right.
7.1 Free Exclusivity Period. For the Free Exclusivity Period, running from Delivery of each Sequence, EVQLV will not disclose, sell, transfer, license or otherwise provide the Same Sequence to any third party (the "Exclusivity Covenant"). EVQLV maintains a record of Sequences subject to an Exclusivity Covenant and checks each Round before Delivery, and any other release of sequences outside EVQLV, against that record. No fee is due and payable by Client for this period.
7.2 Notice. EVQLV will give Client written notice, to the Client notice contact stated in the Order, no later than the Subscription Notice Period before the end of each Sequence's Free Exclusivity Period. The notice will identify the Sequences concerned, the date the Free Exclusivity Period ends, the Subscription Fee, and the Buyout Multiple. If EVQLV gives the notice later than the Subscription Notice Period before the end of a Sequence’s Free Exclusivity Period, that Free Exclusivity Period is extended as to the affected Sequences so that Client has the full Subscription Notice Period plus the Subscription Grace Period after the date of notice in which to elect. That extension is Client’s sole and exclusive remedy for late or omitted notice under this Section 7.2.
7.3 Election. Client may elect, per Sequence, to continue the Exclusivity Covenant by subscribing (a "Sequence Subscription"), at any time up to the end of the Subscription Grace Period. Client may subscribe for some, all, or none of the Sequences delivered in a Round. A Sequence Subscription elected during the Subscription Grace Period runs, and is charged, from the end of the Free Exclusivity Period.
7.4 Effect of a Sequence Subscription. While a Sequence Subscription is in effect, the Exclusivity Covenant continues for that Sequence. The Exclusivity Covenant also continues through the Subscription Grace Period whether or not Client has yet elected, and while a Buyout notice given under Section 7.10(c) is pending. Client may end a Sequence Subscription for any Sequence on thirty (30) days' written notice; Subscription Fees already paid, including prepaid amounts, are not refunded.
7.5 Effect of no subscription. Where Client does not subscribe for a Sequence, or a Sequence Subscription ends, the Exclusivity Covenant as to that Sequence ends. The Sequence is then marked lapsed in the record described in Section 7.1, and EVQLV is no longer restricted from providing the Same Sequence to a third party, though it is not obliged to do so and nothing in these Terms requires or implies that it will. This Section 7.5 does not permit EVQLV to use or disclose Client Data or Client's Confidential Information. Client's ownership of the delivered Sequence under Section 6.1 is unaffected.
7.6 Subscription Fee; escalation. The Subscription Fee is payable monthly in advance, per Sequence, beginning at the end of the Free Exclusivity Period. The first Escalation Interval for a Sequence begins at the end of its Free Exclusivity Period. On each Escalation Date, being the end of each Escalation Interval, the Subscription Fee increases by the Escalation Amount. Where the Escalation Amount is stated as a sum of money, that sum is added to the then-current Subscription Fee. Where it is stated as a percentage, that percentage is applied to the then-current Subscription Fee and compounds.
7.7 Prepayment. Client may elect to prepay a Sequence Subscription annually or for a longer term stated in the Order. Any discount for prepayment is stated in the Order.
7.8 Non-payment. If a Subscription Fee is not paid when due, EVQLV will give Client written notice. Client may cure within thirty (30) days of that notice by paying all unpaid Subscription Fees then outstanding, not only the amount most recently due. If Client does not cure, the Sequence Subscription for the affected Sequences terminates and Section 7.5 applies. Amounts already paid are not refunded.
7.9 Reinstatement. EVQLV may, in its sole discretion, reinstate a terminated Sequence Subscription, on such terms as EVQLV determines at the time, including a Subscription Fee higher than the fee that would have applied had the subscription run continuously. In no case does lapsing and reinstating a Sequence Subscription reset or reduce the Subscription Fee.
7.10 Buyout. Client may purchase a perpetual Exclusivity Covenant for any one or more Sequences (a “Buyout”). Where the Order states a Round Buyout Price, Client may instead buy out all Sequences delivered in a Round at that price.
7.11 Scope of exclusivity. Exclusivity under this Section 7 is limited to the Same Sequence, being 100% identity over the full length of the delivered Sequence. Any substitution, insertion or deletion produces a variant that is not subject to exclusivity. Exclusivity does not (a) grant any target, epitope, field-of-use, indication, modality, or similarity exclusivity; (b) restrict EVQLV's creation, use or provision of different sequences for any target, including for third parties; (c) restrict EVQLV's independent development; and (d) confer any rights in EVQLV Technology. Structural models, coordinate files and visualization materials, if any are delivered, carry no exclusivity of any kind and, as between the Parties, remain the sole and exclusive property of EVQLV. EVQLV grants Client a non-exclusive, non-transferable, royalty-free license to use those materials internally, solely to evaluate and use the Sequences with which they are delivered.
7.12 No third-party effect. EVQLV's covenants in this Section 7 bind EVQLV only. They do not bind any third party and do not restrict independent development by anyone.
7.13 No clearance; possible overlap. Client acknowledges that (a) EVQLV may design, generate and deliver the same or similar Sequences for other clients to the extent permitted by Sections 7.5 and 7.11; (b) EVQLV's check under Section 7.1 is limited to Sequences then subject to an Exclusivity Covenant, and EVQLV does not search, screen or clear any Sequence against third-party rights, against Sequences no longer subject to an Exclusivity Covenant, or against similar but non-identical sequences; and (c) any patent or other right Client obtains in respect of a Sequence is obtained at Client’s own risk. EVQLV has no obligation to notify Client that a similar (non-identical) sequence has been or may be delivered to another client.
7.14 Remedy. If EVQLV breaches the Exclusivity Covenant for a Sequence, Client is entitled to injunctive relief and to a refund of all Subscription Fees and Buyout fees paid for that Sequence. The refund is in addition to, and not limited by, Section 13.5. Except where the breach is intentional, these are Client's sole remedies for that breach.
8.1 EVQLV provides no wet-lab, laboratory, manufacturing, or physical-materials services under these Terms, and EVQLV does not take title to, hold, or ship any physical material. Services of that kind are not part of any Order under these Terms. EVQLV delivers variable domain sequences only and does not deliver full-length, formatted or expression-ready constructs; the format in which Client expresses or uses a Sequence is Client's responsibility.
8.2 The Feasibility Assessment is a separate purchase governed by the Abtique Feasibility Assessment Terms (located at https://www.abtique.com/feasibility-terms). No Order under these Terms includes a Feasibility Assessment. A Feasibility Assessment is ordered separately under those Terms, and these Terms do not apply to it.
8.3 Additional Services. EVQLV may offer additional services from time to time. Such services are purchased by a further Order or statement of work referencing these Terms, and are governed by these Terms together with any additional terms stated in that Order or statement of work. No amendment of these Terms is required.
9.1 "Client Data" means all data, information and materials that Client, or a third party on Client's behalf, provides to EVQLV or generates from its use of the Sequences, including target and epitope information, sequences and structures Client supplies, and Experimental Results. Client retains all rights in Client Data. Client Data does not include any Sequence, or any data, model, output or other material generated by EVQLV, even if related to or derived from Client Data, and no such material is a derivative or improvement of Client Data. Client will not provide personal data to EVQLV, other than business contact information, unless EVQLV agrees in writing.
9.2 Where Client submits Client Data to EVQLV, Client grants EVQLV a non-exclusive, royalty-free license to use it internally, solely to perform the services, including designing Rounds, and to refine or improve Sequences or model performance for Client's own benefit.
9.3 EVQLV will not use Client Data to train, fine-tune, or improve any model, pipeline or method that EVQLV uses for any other client. EVQLV may use Client Data to improve models and methods used exclusively for Client's own programs. EVQLV will not use Client Data in work for third parties and will not publish or share it, except that, unless Client opts out in writing, EVQLV may refer to Client's work in promotional material in anonymized form that discloses no more than the target class. That material will not include Client's identity, any sequence data, the target, the epitope, any personal data, or any other information that could identify Client or its program, unless Client approves in writing.
9.4 Client authorizes EVQLV to process Client Data using EVQLV's own and third-party computational, artificial-intelligence and machine-learning systems to perform the services. EVQLV will keep any third-party system it uses for this purpose under confidentiality and non-use obligations and will not permit it to train on, retain beyond the engagement, or publicly expose Client Data. This authorization is Client's prior written consent for the purposes of any confidentiality agreement between the Parties.
10.1 Fees are stated in the Order. EVQLV invoices on the Effective Date, referencing Client's purchase order number if any, and payment is due net thirty (30) days. Terms in any purchase order or vendor portal do not apply. An Order may state a credit applied under the Abtique Feasibility Assessment Terms.
10.2 Fees exclude taxes other than taxes on EVQLV's net income. Client is responsible for all applicable taxes and governmental charges.
10.3 EVQLV may suspend performance for non-payment. Except as stated in Sections 3.4, 10.4, 17.3 and 18.2, fees are non-refundable on Delivery of the Round to which they relate, and where an Order includes more than one Round, the fees for the Order are non-refundable in full once the Initial Round is delivered, because EVQLV has reserved capacity for the remaining Rounds under Section 4.2. EVQLV may, in its sole discretion and without obligation, credit the value of one undelivered Round against a future Order. Any such credit is a one-time accommodation, has no cash value, is not transferable, and does not create a right to a credit on any other Order. Any refund under the Agreement is limited to amounts Client paid and excludes any credit applied to the Order.
10.4 EVQLV may reject or cancel an Order before beginning work for reasons including feasibility, biosecurity, biosafety, export or sanctions compliance, pricing error, or legal restriction, and will refund any fee paid for work not performed.
11.1 Research use only. Sequences are provided for research use only and not for diagnostic, clinical or therapeutic use unless Client separately obtains all required approvals, at its own cost and responsibility. All deliverables are computational and hypothesis-generating, are not experimentally validated, and, except as stated in a Design Plan under Section 3.7, guarantee no affinity, specificity, developability or other performance characteristic.
11.2 Required approvals. No Sequence or service is cleared or approved by the FDA, EMA or any other regulator. Client is solely responsible for all regulatory, biosafety, IRB and IACUC approvals, facility certifications, permits, validations, and for compliance with all applicable law and third-party intellectual property rights. EVQLV provides no legal, patentability or freedom-to-operate advice and performs no third-party intellectual property diligence.
11.3 Prohibited uses. Client will not use Sequences (a) for gain-of-function work reasonably expected to enhance pathogenicity or transmissibility; (b) in Dual Use Research of Concern categories without approvals; (c) with select agents or contrary to applicable biosafety guidance; (d) contrary to export control or sanctions law; or (e) in any unlawful human, animal or environmental application. EVQLV may suspend or terminate immediately and cooperate with competent authorities if it reasonably suspects a breach of this Section 11.3.
11.4 Export compliance. Client represents that it is not a sanctioned person and is not located in, organized under the laws of, or ordinarily resident in a comprehensively sanctioned country or territory. Each Party will comply with applicable export control and sanctions laws.
12.1 EXCEPT AS STATED IN SECTION 12.3 AND IN ANY PERFORMANCE COMMITMENT UNDER SECTION 3.7, THE SEQUENCES AND ALL RELATED MATERIALS ARE EXPERIMENTAL AND ARE PROVIDED "AS IS" AND "AS AVAILABLE." EVQLV DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING AS TO AFFINITY, SPECIFICITY, CROSS-REACTIVITY, DEVELOPABILITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, RESULTS FROM USE, AND ANY WARRANTY ARISING FROM USAGE OF TRADE OR COURSE OF DEALING. OUTCOMES MAY VARY.
12.2 CLIENT ACKNOWLEDGES THAT ALL SEQUENCES ARE COMPUTATIONALLY GENERATED AND EXPERIMENTAL IN NATURE, AND THAT IT HAS NOT RELIED ON ANY ORAL OR WRITTEN MARKETING OR PROMOTIONAL MATERIAL IN MAKING ITS PURCHASE DECISION.
12.3 Right to grant. EVQLV warrants that it has the right to grant the rights it grants under the Agreement, including the assignment in Section 6.1.
13.1 Indemnification by Client. Client will indemnify, defend and hold harmless EVQLV and its affiliates against third-party claims, and resulting damages, losses, liabilities, costs and expenses, including reasonable attorneys' fees, arising out of (a) Client's use, commercialization, resale, sublicensing, modification, combination or distribution of the Sequences; (b) regulatory or safety matters relating to Client's use; and (c) materials or data Client provides, except to the extent caused by EVQLV's breach of the Agreement or willful misconduct.
13.2 Indemnification by EVQLV. EVQLV will indemnify, defend and hold harmless Client against third-party claims alleging that EVQLV Technology infringes a valid patent, copyright or trade secret. This indemnity does not extend to the Sequences themselves. EVQLV gives no indemnity, representation or warranty that any Sequence does not infringe the rights of any third party, consistent with Sections 11.2 and 12.1.
13.3 Procedure. The indemnified Party must promptly notify the indemnifying Party, tender control of defense and settlement subject to a right to participate at its own expense, and provide reasonable cooperation. No settlement imposing an admission of liability or a non-monetary obligation may be made without the indemnified Party's consent, not unreasonably withheld. Late notice relieves the indemnifying Party only to the extent it is materially prejudiced.
13.4 Exclusion of damages. EXCEPT AS STATED IN SECTION 13.6, NEITHER PARTY IS LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES, OR FOR LOST PROFITS, REVENUE OR DATA, EVEN IF ADVISED OF THE POSSIBILITY.
13.5 Cap. EXCEPT AS STATED IN SECTION 13.6, AND EXCEPT FOR A REFUND UNDER SECTION 7.14, EACH PARTY’S TOTAL LIABILITY ARISING OUT OF OR RELATING TO AN ORDER WILL NOT EXCEED THE FEES PAID TO EVQLV FOR THE ROUNDS PURCHASED UNDER THAT ORDER. Subscription Fees and Buyout fees paid under Section 7 are not included in the amount of the cap.
13.6 Exceptions. Sections 13.4 and 13.5 do not apply to: (a) Client’s obligations under Section 11.3 (Prohibited uses) or Section 11.4 (Export compliance); (b) either Party’s obligations under Sections 13.1 and 13.2; (c) Client’s intentional breach of Section 6.3 or Section 6.5; (d) EVQLV’s intentional breach of Section 9 or Section 14; (e) either Party’s willful misconduct; or (f) Client’s obligation to pay fees due.
14.1 "Confidential Information" means all non-public business, technical, scientific and financial information disclosed by or on behalf of a Party (the "Discloser") to the other Party (the "Recipient") in connection with the Agreement, whether before or after the Effective Date and in any form, that is marked or identified as confidential when disclosed or that a reasonable person would understand to be confidential given its nature and the circumstances of disclosure. Confidential Information excludes information that the Recipient can show by written records (a) is or becomes public through no breach of the Agreement; (b) was lawfully known to the Recipient without restriction before receipt; (c) is independently developed by the Recipient without use of or reference to the Discloser's Confidential Information; or (d) is received from a third party under no duty of confidentiality.
14.2 The Recipient will use Confidential Information solely to perform or receive services under the Agreement, will protect it with at least the care it uses for its own similar information and no less than reasonable care, and may disclose it only to its employees, contractors, advisors and actual or prospective investors or acquirers who need to know it and are bound by written confidentiality obligations no less protective than this Section 14. The Recipient is responsible for any breach of this Section 14 by those persons.
14.3 Client Data and all other materials Client supplies are Client's Confidential Information, including the fact that Client has disclosed or is working on a particular target, epitope, sequence, format or service request. Each Sequence is Client's Confidential Information while an Exclusivity Covenant applies to it, and EVQLV may keep records of each Sequence to perform its obligations under Section 7. EVQLV Technology and each Design Plan are EVQLV's Confidential Information.
14.4 Where disclosure is required by law, the Recipient will promptly notify the Discloser where legally permitted, will reasonably cooperate with any effort by the Discloser to obtain a protective order, and will disclose only what is required.
14.5 Return or destruction. On the Discloser's written request after the last Order ends, the Recipient will return or destroy the Discloser's Confidential Information, except copies kept in routine backups, copies required by law, and records EVQLV keeps under Section 14.3, all of which remain subject to this Section 14.
15.1 Neither Party will issue a press release or public statement referencing the other without prior written consent. On Client's written approval, EVQLV may identify Client by name and logo as a customer in customer lists, on its website and in presentations. For publications, EVQLV will receive customary acknowledgment or co-authorship consistent with journal policy and actual contribution.
16.1 Client is solely responsible for all clearances, approvals and third-party rights necessary for its use, commercialization or patenting of any Sequence, and for preparing and filing any recordation documents and paying related fees.
16.2 On Client's written request and payment of the fees set forth in Section 16.3 (or otherwise agreed to in writing between Client and EVQLV), EVQLV will provide reasonable cooperation limited to (a) confirming inventorship as to EVQLV personnel, (b) executing patent assignment and declaration forms consistent with Section 6, and (c) answering factual inquiries regarding EVQLV's internal dates of creation and the non-use of third-party confidential information. EVQLV is not required to provide notebooks, source code, models, prompts, weights, datasets or other EVQLV Technology. EVQLV will sign confirmatory assignment and inventorship declaration forms under clause (b) without charge, within ten (10) business days after Client's request.
16.3 Except for signing forms under Section 16.2(b), EVQLV's assistance is subject to its prior approval, not to be unreasonably withheld. Client will reimburse EVQLV's reasonable out-of-pocket costs and pay for EVQLV's time at the patent assistance rates stated in Section 2.4. EVQLV has no obligation to draft claims, provide legal opinions, attend hearings, or participate in oppositions, litigation or inter partes proceedings.
16.4 Inventorship is determined under applicable law and is not altered by the Agreement.
17.1 These Terms apply to an Order from the Effective Date until the Order is completed, expires under Section 5, or is terminated.
17.2 EVQLV may suspend or terminate an Order for (a) non-payment; (b) breach of Section 11 or Section 14; or (c) material breach uncured for thirty (30) days after written notice, with no cure period for a violation of law.
17.3 Client may terminate an Order for EVQLV's material breach that remains uncured thirty (30) days after written notice. On such termination EVQLV will refund fees paid for Rounds not delivered. Except as provided in Section 18.2, this is Client’s only termination right; there is no termination for convenience.
17.4 Sections 6, 7, 9, 10, 11, 12, 13, 14, 15, 16 and 18 survive expiration or termination. A Sequence Subscription and a Buyout survive termination of the Order under which the Sequence was delivered, and continue on the terms of Section 7.
18.1 Governing law and disputes. Delaware law governs, without regard to conflicts rules. The Parties will confer in good faith for thirty (30) days after written notice of a dispute. Disputes not resolved are determined by binding JAMS arbitration seated in New York, New York, before a single arbitrator under the JAMS Streamlined Rules. Hearings are held by videoconference unless both Parties agree otherwise, and a dispute in which less than USD $50,000 is claimed is decided on written submissions without a hearing. Either Party may seek injunctive relief, and may bring a claim for unpaid fees, in any court of competent jurisdiction. CLASS WAIVER: ARBITRATION IS ON AN INDIVIDUAL BASIS ONLY; CLASS, COLLECTIVE AND REPRESENTATIVE ACTIONS ARE WAIVED.
18.2 Force majeure. Neither Party is liable for delay or failure to perform caused by an event beyond its reasonable control. This does not excuse payment. If such an event continues for more than ninety (90) days, either Party may terminate the affected Order on written notice, and fees for Rounds not delivered are refunded pro rata.
18.3 Subcontracting. EVQLV may use subcontractors or affiliates, provided EVQLV remains responsible for their performance and binds them to confidentiality and compliance obligations no less protective than these Terms.
18.4 Assignment. Neither Party may assign the Agreement without the other's prior written consent, except that (a) either Party may assign it, on written notice, to a successor in a merger, change of control or sale of all or substantially all of its relevant business or assets, and (b) EVQLV may assign it to an affiliate. Any other assignment is void. Client may transfer a Sequence together with its Exclusivity Covenant on written notice to EVQLV.
18.5 Notices. Notices to EVQLV go to legal@evqlv.com; notices to Client go to the contact stated in the Order. Email notice is effective on the earlier of a non-automated acknowledgment and one business day after sending without bounce-back.
18.6 Entire agreement. The Agreement is the entire agreement on its subject matter and supersedes all prior and contemporaneous understandings. Conflicting terms on any purchase document do not apply. Amendments to an accepted Order must be in writing signed by both Parties.
18.7 The Parties are independent contractors. Counterparts and electronic signatures are effective. If any provision is held unenforceable, it is enforced to the extent permitted and the remainder stands. A delay in enforcing a right is not a waiver of it.
EVQLV, Inc. · 9429 Harding Ave., #199, Surfside, FL 33154 · info@evqlv.com · legal@evqlv.com